FI101793B1 - Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonihappojohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonihappojohdannaisten valmistamiseksi

Info

Publication number
FI101793B1
FI101793B1 FI913236A FI913236A FI101793B1 FI 101793 B1 FI101793 B1 FI 101793B1 FI 913236 A FI913236 A FI 913236A FI 913236 A FI913236 A FI 913236A FI 101793 B1 FI101793 B1 FI 101793B1
Authority
FI
Finland
Prior art keywords
preparation
purinylphosphonic
acid derivatives
therapeutically useful
novel therapeutically
Prior art date
Application number
FI913236A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI913236A (fi
FI101793B (fi
FI913236A0 (fi
Inventor
Serge Halazy
Charles Danzin
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI913236A0 publication Critical patent/FI913236A0/fi
Publication of FI913236A publication Critical patent/FI913236A/fi
Application granted granted Critical
Publication of FI101793B publication Critical patent/FI101793B/fi
Publication of FI101793B1 publication Critical patent/FI101793B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI913236A 1990-07-04 1991-07-03 Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonihappojohdannaisten valmistamiseksi FI101793B1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90401940 1990-07-04
EP90401940 1990-07-04

Publications (4)

Publication Number Publication Date
FI913236A0 FI913236A0 (fi) 1991-07-03
FI913236A FI913236A (fi) 1992-01-05
FI101793B FI101793B (fi) 1998-08-31
FI101793B1 true FI101793B1 (fi) 1998-08-31

Family

ID=8205733

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913236A FI101793B1 (fi) 1990-07-04 1991-07-03 Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonihappojohdannaisten valmistamiseksi

Country Status (22)

Country Link
US (2) US5538978A (de)
EP (1) EP0465297B1 (de)
JP (1) JP3006919B2 (de)
KR (1) KR100217807B1 (de)
CN (1) CN1031713C (de)
AT (1) ATE133678T1 (de)
AU (1) AU643533B2 (de)
CA (1) CA2045783C (de)
DE (1) DE69116750T2 (de)
DK (1) DK0465297T3 (de)
ES (1) ES2085446T3 (de)
FI (1) FI101793B1 (de)
GR (1) GR3019793T3 (de)
HU (1) HU208832B (de)
IE (1) IE72096B1 (de)
IL (1) IL98702A (de)
MX (1) MX9203682A (de)
NO (1) NO180541C (de)
NZ (1) NZ238774A (de)
PT (1) PT98198B (de)
TW (1) TW199896B (de)
ZA (1) ZA914978B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE133678T1 (de) * 1990-07-04 1996-02-15 Merrell Dow Pharma 9-purinyl-phosphonsäurederivate
EP0531597A1 (de) * 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Ungesättigte azyklische Phosphonsäure Purinderivats und Pyrimidinderivate
US5817660A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5817672A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5723466A (en) * 1991-12-06 1998-03-03 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5817661A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
AU658698B2 (en) * 1991-12-06 1995-04-27 Aventis Pharmaceuticals Inc. Novel trans cyclopentanyl purine analogs useful as immunosuppressants
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
EP0719274A1 (de) * 1993-09-17 1996-07-03 Gilead Sciences, Inc. Verfahren zur dosierung von therapeutischer verbindungen
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
EP2336133A1 (de) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purinanaloga mit HSP90-inhibierender Wirkung
BR0309557A (pt) 2002-04-26 2005-03-01 Gilead Sciences Inc Inibidores da transcriptase reversa não nucleosìdeos
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
AU2004233897A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
EP1678321A1 (de) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Verfahren und zusammensetzungen zur identifizierung therapeutischer verbindungen
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
UA88313C2 (ru) 2004-07-27 2009-10-12 Гилиад Сайенсиз, Инк. Фосфонатные аналоги соединений ингибиторов вич
CA2602257A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
US8158108B2 (en) * 2006-06-28 2012-04-17 S.C. Johnson & Son, Inc. VOC-free compressed gas aerosol compositions
US8178078B2 (en) 2008-06-13 2012-05-15 S.C. Johnson & Son, Inc. Compositions containing a solvated active agent suitable for dispensing as a compressed gas aerosol
EA018308B1 (ru) 2008-07-08 2013-07-30 Джилид Сайэнс, Инк. Соли соединений ингибиторов вич
KR101692133B1 (ko) 2015-01-13 2017-01-02 연세대학교 원주산학협력단 폴리이미드 수용액을 이용한 폴리이미드 성형방법
CN105061504A (zh) * 2015-09-16 2015-11-18 湖南大学 P-炔基磷酸酯类化合物的制备方法
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288098C (en) * 1984-08-24 1991-08-27 Richard L. Tolman 4-(guanin-9-yl)butanals and their 3-oxa, 3-thia and 2-ene derivatives having antiviral and antitumor activity
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
EP0328834A1 (de) * 1988-02-16 1989-08-23 Merrell Dow Pharmaceuticals Inc. Aspartat Transcarbamylase Inhibitoren
EP0335770B1 (de) * 1988-04-01 1997-01-15 Merrell Pharmaceuticals Inc. Derivate von Fluorphosphonat-Nukleotiden
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
EP0338887B1 (de) * 1988-04-19 1993-12-08 Merrell Dow Pharmaceuticals Inc. Phosphonoalkylpurin-Derivate
EP0338168A1 (de) * 1988-04-19 1989-10-25 Merrell Dow Pharmaceuticals Inc. Phosphonoalkylpurin-Derivate
JPH02124898A (ja) * 1988-04-28 1990-05-14 Nippon Kayaku Co Ltd プリン塩基を有する新規化合物、その用途及び中間体
JPH02124897A (ja) * 1988-07-28 1990-05-14 Nippon Kayaku Co Ltd エリスロフラノシルヌクレオシド誘導体の製造法及び新規誘導体
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
DE58902899D1 (de) * 1988-12-14 1993-01-14 Ciba Geigy Ag 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
ATE133678T1 (de) * 1990-07-04 1996-02-15 Merrell Dow Pharma 9-purinyl-phosphonsäurederivate
EP0468119A1 (de) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Neue Carbocyclische Analoge einiger Nukleoside
EP0477454A1 (de) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Phosphonatderivate von bestimmten Nucleosiden

Also Published As

Publication number Publication date
DK0465297T3 (da) 1996-02-19
DE69116750T2 (de) 1996-11-14
NO180541B (no) 1997-01-27
US5527803A (en) 1996-06-18
FI913236A (fi) 1992-01-05
TW199896B (de) 1993-02-11
IL98702A0 (en) 1992-07-15
NO912606L (no) 1992-01-06
NZ238774A (en) 1993-08-26
JP3006919B2 (ja) 2000-02-07
NO912606D0 (no) 1991-07-03
DE69116750D1 (de) 1996-03-14
HU912253D0 (en) 1991-12-30
EP0465297B1 (de) 1996-01-31
GR3019793T3 (en) 1996-07-31
ATE133678T1 (de) 1996-02-15
JPH04253989A (ja) 1992-09-09
EP0465297A1 (de) 1992-01-08
HUT59151A (en) 1992-04-28
PT98198A (pt) 1992-04-30
CN1058021A (zh) 1992-01-22
IE912329A1 (en) 1992-01-15
ZA914978B (en) 1992-04-29
FI101793B (fi) 1998-08-31
FI913236A0 (fi) 1991-07-03
IL98702A (en) 1997-02-18
CA2045783A1 (en) 1992-01-05
IE72096B1 (en) 1997-03-12
MX9203682A (es) 1992-08-01
ES2085446T3 (es) 1996-06-01
PT98198B (pt) 1998-12-31
KR920002622A (ko) 1992-02-28
AU643533B2 (en) 1993-11-18
CN1031713C (zh) 1996-05-01
KR100217807B1 (ko) 1999-10-01
US5538978A (en) 1996-07-23
AU7941491A (en) 1992-01-09
CA2045783C (en) 2001-09-18
HU208832B (en) 1994-01-28
NO180541C (no) 1997-05-07

Similar Documents

Publication Publication Date Title
FI101793B1 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonihappojohdannaisten valmistamiseksi
IL101931A0 (en) Processes for the diastereoselective synthesis of nucleosides,and hydrofuran derivatives for use therein
DE69333109D1 (de) Therapeutische nukleoside
EP0152965A3 (en) Process for preparing 2,6-substituted-9-(1,3-dihydroxy-2-propoxy-menthyl)-purines and certain derivatives
FI885094A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen 2',3'-dideoksi-3'-fluoripyrimidiini- tai -puriininukleosidin valmistamiseksi
ZA892284B (en) Novel fluorophosphonate nucleotide derivatives
NO974512L (no) Fremgangsmåte for syntese av nukleosid-analoger
FI863729A (fi) Menetelmä terapeuttisesti käyttökelpoisten 3'-atsido nukleosidien valmistamiseksi